GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. reported its second-quarter 2026 financial results, highlighted by the acquisition of Intelerad for approximately $2.293 billion in cash. The company achieved total revenues of $5.295 billion, an increase from $5.007 billion in the prior year, with net income attributable to GE HealthCare rising to $561 million ($1.24 diluted EPS) from $486 million ($1.06 diluted EPS). The company also announced a strategic segment restructuring, combining Imaging and Advanced Visualization Solutions into a new Advanced Imaging Solutions (AIS) segment. Cash from operating activities for the six months ended June 30, 2026, was $458 million.

GE HealthCare Technologies Inc. announced a strategic organizational change, combining its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions (AIS) segment. This restructuring aims to enhance execution, accelerate innovation, and create efficiencies. The company now has three reportable segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). The filing provides recast unaudited historical financial information reflecting this new segment structure, including detailed revenues and expenses for the new segments.

GE HealthCare reported strong second quarter 2026 financial results, with total revenues increasing 5.7% to $5.3 billion and organic revenue growth of 3.5%. Diluted EPS rose 16.5% to $1.24, and the company achieved record organic orders growth of 11.1% and a backlog of $23.9 billion. Despite these gains, the Patient Care Solutions segment continued to be challenged, prompting a review of strategic options. The company reaffirmed its full-year 2026 guidance.

GE HealthCare announced that James K. Saccaro will resign as Chief Financial Officer, effective August 14, 2026, to pursue an opportunity outside the medical technology industry. George Newcomb, Controller and Chief Accounting Officer, has been named interim CFO. Concurrently, the company reported preliminary unaudited second quarter 2026 results, expecting year-over-year revenue growth of 5.7% and organic revenue growth of 3.5%. Adjusted EPS is anticipated to be ahead of prior expectations, and the company reaffirmed its full-year 2026 guidance.

GE HealthCare Technologies Inc. held its annual meeting on May 7, 2026, where stockholders elected eight directors, approved named executive officers’ compensation in an advisory vote, and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Additionally, the Board of Directors appointed Rodney F. Hochman as the independent lead director and Anne T. Madden as chairperson of the Nominating and Governance Committee, effective the same day.

GE HealthCare Technologies Inc. acquired Intelerad for approximately $2.297 billion in cash, enhancing its Imaging segment with medical imaging software and digital workflow solutions. For Q1 2026, the company reported total revenues of $5.131 billion, a 7.4% increase year-over-year, but net income attributable to GE HealthCare decreased by 31.0% to $389 million, resulting in diluted EPS of $0.85. The decrease in net income was impacted by higher operating expenses and acquisition-related costs, despite improved cash from operating activities.

GE HealthCare reported Q1 2026 revenue of $5.1 billion, up 7.4% (2.9% organic), meeting the high end of expectations, driven by strong performance in Pharmaceutical Diagnostics and Imaging. However, profitability was impacted by a discrete PDx supplier issue and significant increases in memory chip, oil, and freight costs, leading to a 31.0% decrease in net income and a 2.0% decrease in Adjusted EPS. The company reaffirmed its full-year topline growth guidance but reduced its profit and Free cash flow outlook due to these inflationary pressures, while also completing the acquisition of Intelerad for $2.3 billion.